Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18972971 | 0.90 | DPP4 (0.33) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL18077443 | 0.86 | GABRA2 (0.35) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL18862134 | 0.82 | GABRA2 (0.32) | GABRA2GABRB2 | |
| SCHEMBL18367628 | 0.81 | DPP4 (0.33) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL20997333 | 0.81 | DPP4 (0.33) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL10089709 | 0.80 | GABRA2 (0.42) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL21163393 | 0.80 | — | — | |
| SCHEMBL19589452 | 0.78 | GRN (0.37) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL18812323 | 0.77 | GABRA2 (0.37) | GABRA2GABRB2HRH4HRH3DPP4 | |
| SCHEMBL22030529 | 0.77 | GABRA2 (0.37) | GABRA2GABRB2HRH4HRH3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-04-13 | — | — | US | disclosed |
| US-20220017495-A1 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-01-20 | — | — | US | disclosed |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | GABRA2 3100/4885GABRB2 2439/4885HRH4 46/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | GABRA2 1471/4885GABRB2 1542/4885HRH4 1477/4885 |
| US-20230114807-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | GABRA2 3100/4885GABRB2 2439/4885HRH4 46/4885 |
| US-20220017495-A1 | CONJUGATES OF BIVALENT EVANS BLUE DYE DERIVATIVES AND METHODS OF USE | NUCB2, RNPEP, MME | GABRA2 2917/4885GABRB2 1510/4885HRH4 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.